Cybin Secures $175 Million in Funding to Advance Mental Health Therapeutics
Cybin Inc. has closed a $175 million registered direct offering with top healthcare investors, providing critical capital to advance its Phase 3 clinical programs for novel mental health treatments addressing major depressive disorder and generalized anxiety disorder.
Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company, has completed a registered direct offering generating approximately $175 million in gross proceeds. The financing involved the sale of 22,277,750 common shares and 4,605,500 pre-funded warrants, each priced at $6.51. The offering attracted participation from prominent healthcare investors including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, and Adage Capital Partners.
Each investment unit included 0.35 of a warrant exercisable at $8.14 per share before June 30, 2027, or earlier under specified conditions. Jefferies, TD Cowen, and Cantor served as joint lead placement agents for the offering, with Bloom Burton Securities Inc. acting as placement agent. The substantial funding comes at a critical juncture for the company as it advances its late-stage clinical programs.
The capital infusion supports Cybin's mission to revolutionize mental healthcare through developing next-generation treatment options for conditions with significant unmet medical needs. The company's lead candidate, CYB003, represents a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational therapy has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, recognizing its potential to address serious conditions where current treatments are inadequate.
Additional details about the company's progress and developments are available in their newsroom at https://ibn.fm/CYBN. Cybin is also advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, targeting multiple psychiatric conditions through novel mechanisms of action.
The successful financing round demonstrates strong investor confidence in Cybin's approach to mental health therapeutics and its potential to transform treatment paradigms. The participation of leading healthcare investment firms signals recognition of the company's scientific approach and the substantial market opportunity in addressing mental health conditions that affect millions worldwide. This funding positions Cybin to accelerate its clinical development programs and potentially bring innovative treatments to patients suffering from debilitating mental health disorders.